Vanguard Global Advisers
ALDX icon

Vanguard Global Advisers’s Aldeyra Therapeutics ALDX Stock Holding History

Vanguard Global Advisers’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.7K Hold
17,687
– – ﹤0.01% 3160
2026
Q1 		$29.9K Buy
+17,687
New +$77.5K ﹤0.01% 3196

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Vanguard Global Advisers's ALDX Position: Q2 2026 in Review

Vanguard Global Advisers held its Aldeyra Therapeutics (ALDX) position steady in Q2 2026 at 17,687 shares worth $37.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3160.

Vanguard Global Advisers first reported a position in ALDX in Q1 2026 and has held it in 2 quarters since. 107 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • Vanguard Global Advisers held 17,687 shares of Aldeyra Therapeutics worth $37.7K as of Q2 2026.
  • Vanguard Global Advisers left its Aldeyra Therapeutics share count unchanged in Q2 2026.
  • Aldeyra Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3160 holding.
  • Vanguard Global Advisers first reported a position in Aldeyra Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 107 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.